The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Nuclear Medicine Diagnostic (SPECT and PET) Market Research Report 2025
Synopsis
The main difference between SPECT and PET scans is the type of radiotracers used. While SPECT scans measure gamma rays, the decay of the radiotracers used with PET scans produce small particles called positrons. A positron is a particle with roughly the same mass as an electron but oppositely charged.
The global Nuclear Medicine Diagnostic (SPECT and PET) market was valued at US$ 3789.6 million in 2023 and is anticipated to reach US$ 4463.5 million by 2030, witnessing a CAGR of 2.4% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Nuclear Medicine Diagnostic (SPECT and PET), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nuclear Medicine Diagnostic (SPECT and PET).
Report Scope
The Nuclear Medicine Diagnostic (SPECT and PET) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nuclear Medicine Diagnostic (SPECT and PET) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nuclear Medicine Diagnostic (SPECT and PET) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GE Healthcare
Siemens Healthineers
Philips Healthcare
Mediso
Spectrum Dynamics
Bruker
SurgicEye
MIE
MILabs
Segment by Type
SPECT
PET
Segment by Application
Oncology
Cardiology
Neurology
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Nuclear Medicine Diagnostic (SPECT and PET) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Nuclear Medicine Diagnostic (SPECT and PET) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The main difference between SPECT and PET scans is the type of radiotracers used. While SPECT scans measure gamma rays, the decay of the radiotracers used with PET scans produce small particles called positrons. A positron is a particle with roughly the same mass as an electron but oppositely charged.
The global Nuclear Medicine Diagnostic (SPECT and PET) market was valued at US$ 3789.6 million in 2023 and is anticipated to reach US$ 4463.5 million by 2030, witnessing a CAGR of 2.4% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Nuclear Medicine Diagnostic (SPECT and PET), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nuclear Medicine Diagnostic (SPECT and PET).
Report Scope
The Nuclear Medicine Diagnostic (SPECT and PET) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nuclear Medicine Diagnostic (SPECT and PET) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nuclear Medicine Diagnostic (SPECT and PET) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GE Healthcare
Siemens Healthineers
Philips Healthcare
Mediso
Spectrum Dynamics
Bruker
SurgicEye
MIE
MILabs
Segment by Type
SPECT
PET
Segment by Application
Oncology
Cardiology
Neurology
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Nuclear Medicine Diagnostic (SPECT and PET) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Nuclear Medicine Diagnostic (SPECT and PET) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Nuclear Medicine Diagnostic (SPECT and PET) Market Overview
1.1 Product Overview and Scope of Nuclear Medicine Diagnostic (SPECT and PET)
1.2 Nuclear Medicine Diagnostic (SPECT and PET) Segment by Type
1.2.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Market Value Comparison by Type (2024-2030)
1.2.2 SPECT
1.2.3 PET
1.3 Nuclear Medicine Diagnostic (SPECT and PET) Segment by Application
1.3.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Market Value by Application: (2024-2030)
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neurology
1.3.5 Others
1.4 Global Nuclear Medicine Diagnostic (SPECT and PET) Market Size Estimates and Forecasts
1.4.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue 2019-2030
1.4.2 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales 2019-2030
1.4.3 Global Nuclear Medicine Diagnostic (SPECT and PET) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Nuclear Medicine Diagnostic (SPECT and PET) Market Competition by Manufacturers
2.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Nuclear Medicine Diagnostic (SPECT and PET) Average Price by Manufacturers (2019-2024)
2.4 Global Nuclear Medicine Diagnostic (SPECT and PET) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Nuclear Medicine Diagnostic (SPECT and PET), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Nuclear Medicine Diagnostic (SPECT and PET), Product Type & Application
2.7 Nuclear Medicine Diagnostic (SPECT and PET) Market Competitive Situation and Trends
2.7.1 Nuclear Medicine Diagnostic (SPECT and PET) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Nuclear Medicine Diagnostic (SPECT and PET) Players Market Share by Revenue
2.7.3 Global Nuclear Medicine Diagnostic (SPECT and PET) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Nuclear Medicine Diagnostic (SPECT and PET) Retrospective Market Scenario by Region
3.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Nuclear Medicine Diagnostic (SPECT and PET) Global Nuclear Medicine Diagnostic (SPECT and PET) Sales by Region: 2019-2030
3.2.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales by Region: 2019-2024
3.2.2 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales by Region: 2025-2030
3.3 Global Nuclear Medicine Diagnostic (SPECT and PET) Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Region: 2019-2030
3.3.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Region: 2019-2024
3.3.2 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Region: 2025-2030
3.4 North America Nuclear Medicine Diagnostic (SPECT and PET) Market Facts & Figures by Country
3.4.1 North America Nuclear Medicine Diagnostic (SPECT and PET) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Nuclear Medicine Diagnostic (SPECT and PET) Sales by Country (2019-2030)
3.4.3 North America Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Nuclear Medicine Diagnostic (SPECT and PET) Market Facts & Figures by Country
3.5.1 Europe Nuclear Medicine Diagnostic (SPECT and PET) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Nuclear Medicine Diagnostic (SPECT and PET) Sales by Country (2019-2030)
3.5.3 Europe Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nuclear Medicine Diagnostic (SPECT and PET) Market Facts & Figures by Country
3.6.1 Asia Pacific Nuclear Medicine Diagnostic (SPECT and PET) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Nuclear Medicine Diagnostic (SPECT and PET) Sales by Country (2019-2030)
3.6.3 Asia Pacific Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Nuclear Medicine Diagnostic (SPECT and PET) Market Facts & Figures by Country
3.7.1 Latin America Nuclear Medicine Diagnostic (SPECT and PET) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Nuclear Medicine Diagnostic (SPECT and PET) Sales by Country (2019-2030)
3.7.3 Latin America Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Nuclear Medicine Diagnostic (SPECT and PET) Market Facts & Figures by Country
3.8.1 Middle East and Africa Nuclear Medicine Diagnostic (SPECT and PET) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Nuclear Medicine Diagnostic (SPECT and PET) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales by Type (2019-2030)
4.1.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales by Type (2019-2024)
4.1.2 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales by Type (2025-2030)
4.1.3 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales Market Share by Type (2019-2030)
4.2 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Type (2019-2030)
4.2.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Type (2019-2024)
4.2.2 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Type (2025-2030)
4.2.3 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue Market Share by Type (2019-2030)
4.3 Global Nuclear Medicine Diagnostic (SPECT and PET) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales by Application (2019-2030)
5.1.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales by Application (2019-2024)
5.1.2 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales by Application (2025-2030)
5.1.3 Global Nuclear Medicine Diagnostic (SPECT and PET) Sales Market Share by Application (2019-2030)
5.2 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Application (2019-2030)
5.2.1 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Application (2019-2024)
5.2.2 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue by Application (2025-2030)
5.2.3 Global Nuclear Medicine Diagnostic (SPECT and PET) Revenue Market Share by Application (2019-2030)
5.3 Global Nuclear Medicine Diagnostic (SPECT and PET) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GE Healthcare
6.1.1 GE Healthcare Corporation Information
6.1.2 GE Healthcare Description and Business Overview
6.1.3 GE Healthcare Nuclear Medicine Diagnostic (SPECT and PET) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GE Healthcare Nuclear Medicine Diagnostic (SPECT and PET) Product Portfolio
6.1.5 GE Healthcare Recent Developments/Updates
6.2 Siemens Healthineers
6.2.1 Siemens Healthineers Corporation Information
6.2.2 Siemens Healthineers Description and Business Overview
6.2.3 Siemens Healthineers Nuclear Medicine Diagnostic (SPECT and PET) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Siemens Healthineers Nuclear Medicine Diagnostic (SPECT and PET) Product Portfolio
6.2.5 Siemens Healthineers Recent Developments/Updates
6.3 Philips Healthcare
6.3.1 Philips Healthcare Corporation Information
6.3.2 Philips Healthcare Description and Business Overview
6.3.3 Philips Healthcare Nuclear Medicine Diagnostic (SPECT and PET) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Philips Healthcare Nuclear Medicine Diagnostic (SPECT and PET) Product Portfolio
6.3.5 Philips Healthcare Recent Developments/Updates
6.4 Mediso
6.4.1 Mediso Corporation Information
6.4.2 Mediso Description and Business Overview
6.4.3 Mediso Nuclear Medicine Diagnostic (SPECT and PET) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mediso Nuclear Medicine Diagnostic (SPECT and PET) Product Portfolio
6.4.5 Mediso Recent Developments/Updates
6.5 Spectrum Dynamics
6.5.1 Spectrum Dynamics Corporation Information
6.5.2 Spectrum Dynamics Description and Business Overview
6.5.3 Spectrum Dynamics Nuclear Medicine Diagnostic (SPECT and PET) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Spectrum Dynamics Nuclear Medicine Diagnostic (SPECT and PET) Product Portfolio
6.5.5 Spectrum Dynamics Recent Developments/Updates
6.6 Bruker
6.6.1 Bruker Corporation Information
6.6.2 Bruker Description and Business Overview
6.6.3 Bruker Nuclear Medicine Diagnostic (SPECT and PET) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bruker Nuclear Medicine Diagnostic (SPECT and PET) Product Portfolio
6.6.5 Bruker Recent Developments/Updates
6.7 SurgicEye
6.6.1 SurgicEye Corporation Information
6.6.2 SurgicEye Description and Business Overview
6.6.3 SurgicEye Nuclear Medicine Diagnostic (SPECT and PET) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 SurgicEye Nuclear Medicine Diagnostic (SPECT and PET) Product Portfolio
6.7.5 SurgicEye Recent Developments/Updates
6.8 MIE
6.8.1 MIE Corporation Information
6.8.2 MIE Description and Business Overview
6.8.3 MIE Nuclear Medicine Diagnostic (SPECT and PET) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 MIE Nuclear Medicine Diagnostic (SPECT and PET) Product Portfolio
6.8.5 MIE Recent Developments/Updates
6.9 MILabs
6.9.1 MILabs Corporation Information
6.9.2 MILabs Description and Business Overview
6.9.3 MILabs Nuclear Medicine Diagnostic (SPECT and PET) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 MILabs Nuclear Medicine Diagnostic (SPECT and PET) Product Portfolio
6.9.5 MILabs Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nuclear Medicine Diagnostic (SPECT and PET) Industry Chain Analysis
7.2 Nuclear Medicine Diagnostic (SPECT and PET) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nuclear Medicine Diagnostic (SPECT and PET) Production Mode & Process
7.4 Nuclear Medicine Diagnostic (SPECT and PET) Sales and Marketing
7.4.1 Nuclear Medicine Diagnostic (SPECT and PET) Sales Channels
7.4.2 Nuclear Medicine Diagnostic (SPECT and PET) Distributors
7.5 Nuclear Medicine Diagnostic (SPECT and PET) Customers
8 Nuclear Medicine Diagnostic (SPECT and PET) Market Dynamics
8.1 Nuclear Medicine Diagnostic (SPECT and PET) Industry Trends
8.2 Nuclear Medicine Diagnostic (SPECT and PET) Market Drivers
8.3 Nuclear Medicine Diagnostic (SPECT and PET) Market Challenges
8.4 Nuclear Medicine Diagnostic (SPECT and PET) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
